Shanghai Universal Biotech Co.Ltd. (301166) Fair Value & Analysis
Healthcare · CN · Market cap 2.3B CNY
Strengths
Risks
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 10 days ago
Share price +25.2% over the past month.
A solid business, but screening 40% overvalued on our models.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥22.81). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥12.05 to ¥22.81) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
56‑month range ¥22.92 – ¥122.84 · fair‑value band ¥12.05 – ¥22.81 · the ¥30.64 price screens above the ¥18.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Shanghai Universal Biotech Co.Ltd. (301166) currently trades at ¥30.64, while our model-based Fair Value estimate is ¥18.25, implying the stock looks roughly 40.4% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Shanghai Universal Biotech Co.Ltd. generated revenue of 1.1B CNY at a net margin of -2.2%. Revenue grew 19.8% year over year. It earns a return on equity of -1.3%. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥12.05 (bear case) to ¥22.81 (bull case); at ¥30.64, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -63% fair-value upside, at -40%, 301166 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 301166 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as immunology reagents, molecular biology reagents, cell biology reagents and biochemical reagents.
Full company description
Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as immunology reagents, molecular biology reagents, cell biology reagents and biochemical reagents. It also provides technical services, technology promotion, technology information exchange, scientific and technology training, technology consulting, technology incubation and other services, as well as experimental services and software solutions. The company also sells products online. It serves colleges and universities, research institutes, hospitals, and biomedical companies. The company was founded in 2004 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Universal Biotech Co.Ltd. reported revenue of ¥1.1B in FY2025 versus ¥1.1B in FY2021, a compound −0.6%/yr. Reported net income was −¥22.9M in FY2025.
301166 screens 40% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$102.40 | HK$19.72 | -81% |
| Genmab A/S GMAB | kr 2,104 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
| Biocon Limited BIOCON | ₹417.50 | ₹52.10 | -88% |
Compare Shanghai Universal Biotech Co.Ltd. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shanghai Universal Biotech Co.Ltd. (301166) overvalued or undervalued?
What is the fair value of 301166?
What is the quality score of 301166?
What is the revenue of Shanghai Universal Biotech Co.Ltd. (301166)?
What is the net profit margin of 301166?
Does Shanghai Universal Biotech Co.Ltd. pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Universal Biotech Co.Ltd. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.